Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

Manipal Institute of Virology (MIV) celebrated its Annual Day and Alumni Meet 2025 at Dr TMA Pai Auditorium, MAHE, Manipal, ...

Shares of Kestra Medical, a wearable cardiac device maker, soared in the company’s public debut this week. Meanwhile, Discord is said to be in ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

therapy Entyvio (vedolizumab), an alpha-4 beta-7 integrin antagonist that made more than $5 billion in sales in 2023, is slated for 2026. Some of the cash raised in the IPO is also set aside for ...

New Delhi: Mylan Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

In a US study, researchers found that 35% of adults with IBD screened positive for spondyloarthritis, despite having no known SpA diagnosis.

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous induction therapy in patients with moderately to severely active ulcerative colitis.

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.